Answers are grounded in this paper and cite their sources.
We conducted a post hoc analysis of the EB-StaR study (NCT02993211) to assess the impact of intravesical bacillus Calmette-Guérin (BCG) therapy following en bloc resection of bladder tumour (ERBT) or standard resection (SR) in patients with non-muscle-invasive bladder cancer (NMIBC). The outcome measures were the 1-yr recurrence and progression rates. Among the 276 patients included in the analysis, 1-yr recurrence rates were 33% (95% confidence interval [CI] 21-43%) in the ERBT alone group versus 41% (95% CI 30-50%) in the SR alone group (p = 0.02); and 5% (95% CI 0-14%) in the ERBT + BCG group versus 26% (95% CI 5.8-42%) in the SR + BCG group (p = 0.059). The 1-yr progression rates were 0% in the ERBT alone group versus 2% (95% CI 0-4.6%) in the SR alone group (p = 0.13); and 0% in the ERBT + BCG group versus 5.6% (95% CI 0-16%) in the SR + BCG group (p = 0.4). The combination of ERBT and intravesical BCG therapy appeared to yield excellent oncological control, resulting in a 1-yr recurrence rate of 5% among patients with high-risk NMIBC. Good-quality surgery plus good adjuvant therapy should be considered vital components in optimising long-term oncological outcomes in NMIBC.
No takes yet. Share an insight, caveat, or question.
Teoh et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: